Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
ConclusionsWe identified molecular characteristics associated to TMZ sensitivity, and illustrate the potential clinical value of a ML model trained from pharmacogenomic profiling of patient-derived GSC against IDH-wt GBMs.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
More News: Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Glioma | Learning | Temodar | Universities & Medical Training